Latanoprost Rivopharm

Latanoprost, the active ingredient in Latanoprost Rivopharm, is a prostaglandin F2α analog presented as eye drops for ocular administration. It reduces intra‑ocular pressure by enhancing aqueous humor outflow, and is indicated for the treatment of primary open‑angle glaucoma and ocular hypertension in adult patients.

GNH USA supplies Latanoprost Rivopharm as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated channels. The company adheres to EU quality standards and supports global procurement for ophthalmic therapies.

Latanoprost is a prostaglandin analog used in ocular hypotensive therapy to manage elevated intra‑ocular pressure.

Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow disease progression. Ocular hypertension: reduces pressure to prevent conversion to glaucoma. Secondary open‑angle glaucoma: assists in intra‑ocular pressure reduction when other therapies are insufficient.

Latanoprost may cause ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia. - Eye irritation or foreign‑body sensation. - Increased eyelash growth. - Darkening of the iris. - Blurred vision. - Mild eye pain.

Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema). - Uveitis or intra‑ocular inflammation. - Corneal edema or clouding. - Persistent eye inflammation. - Vision loss. - Sudden increase in intra‑ocular pressure.

Before initiating therapy, consider the following precautions.

Assess baseline intra‑ocular pressure: ensure appropriate monitoring. Monitor iris color change: inform patients of possible permanent darkening. Avoid use in patients with known hypersensitivity to latanoprost or excipients. Caution in active ocular infection: defer treatment until resolved. Use with care in patients with a history of herpetic eye disease. Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost may interact with other ocular or systemic agents.

Major Interactions (Avoid): - Other prostaglandin analog eye drops: concurrent use may cause excessive IOP reduction. - Systemic carbonic anhydrase inhibitors: may potentiate IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: monitor intra‑ocular pressure for additive effect. - Alpha‑agonist eye drops: observe for excessive pressure lowering. - Topical corticosteroids: may diminish latanoprost efficacy and increase IOP.